Bosutinib
- Generic Name
- Bosutinib
- Brand Names
- Bosulif
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29Cl2N5O3
- CAS Number
- 380843-75-4
- Unique Ingredient Identifier
- 5018V4AEZ0
- Background
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion prote...
- Indication
用于治疗对既往治疗无效的慢性、加速期或急变期Ph+的慢性粒细胞白血病（CML）患者。
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Effect of Rifampin on Bosutinib When Both Are Given to Healthy People
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00725426
Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2009-02-06
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00721474
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 502
- Registration Number
- NCT00574873
- Locations
- 🇺🇸
Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸Robert A Moss, MD, FACP, Inc, Fountain Valley, California, United States
🇺🇸Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 571
- Registration Number
- NCT00261846
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦University Health Network Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT00195260
- Locations
- 🇺🇸
Pfizer Investigational Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.